Sphingolipids are bioactive metabolites known for their roles in human metabolism and disease1,2. They regulate complex cellular processes such as cell migration, cell survival and death, cell movement, vesicular trafficking, cellular invasion and metastasis, angiogenesis, and the production of cytokines1,2,3,4,5,6,7,8,9. Defects in the regulation of sphingolipid metabolism contribute to the initiation and progression of cancers, determine how aggressive cancers are, and how cancers respond to and develop resistance to therapy3,10. Therefore, because of these broad impacts on the etiology of disease, analytical methods that can precisely establish disease-specific sphingolipid alterations are important tools. Mass spectrometry (MS) is the most accurate and reliable method to analyze sphingolipid alterations.
Human specimens that can be used for the analysis of sphingolipid alterations can be obtained prospectively from the surgical suite or retrospectively from tissue biorepositories. Fresh tissues from surgery are advantageous because they can be directly analyzed by MS or other analytical methods. However, acquiring tissues prospectively has administrative, technical, and logistical hurdles, and collecting sufficient specimens to reach statistical power can be challenging. Obtaining tissues from biorepositories is advantageous because they can be acquired retrospectively, in large numbers, and biorepositories confirm histology and pathology, use standard operating procedures to cryogenically preserve and store tissues, and can provide clinicopathological data that can be used for correlation analyses. However, to preserve molecular and structural features, biorepositories may cryopreserve tissues by embedding them in optimal cutting temperature (OCT) compound, which we have shown interferes with data normalization assays and the quantification of sphingolipids by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS)11. It has also been shown that polyvinyl alcohol and polyethylene glycol, the primary components in OCT compound, result in ion suppression in other MS analysis platforms12,13,14,15. Therefore, OCT compound must be removed from tissues prior to sphingolipidomic analysis by MS.
In a previous report, we have validated a protocol for the removal of OCT compound from human specimens for LC-ESI-MS/MS analysis11 and the methodology used for weighing tissues for data normalization11. Here, we detail the steps of the sphingolipidomic OCT compound-removal protocol (sOCTrP) and show representative data from human lung adenocarcinoma tumors and normal adjacent uninvolved tissues.